Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Genmab AS's Enterprise Value is MXN350,409 Mil.
Genmab AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was MXN22,168 Mil. Therefore, Genmab AS's EV-to-EBIT ratio for today is 15.81.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Genmab AS's Enterprise Value is MXN350,409 Mil.
Genmab AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was MXN23,700 Mil. Therefore, Genmab AS's EV-to-EBITDA ratio for today is 14.78.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Genmab AS's Enterprise Value is MXN350,409 Mil.
Genmab AS's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was MXN71,372 Mil. Therefore, Genmab AS's EV-to-Revenue ratio for today is 4.91.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Genmab AS's Enterprise Value is MXN350,409 Mil.
Genmab AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN15,924 Mil. Therefore, Genmab AS's EV-to-FCF ratio for today is 22.00.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Genmab AS (MEX:GMABN) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Genmab AS's current Enterprise Value is MXN350,409 Mil.
Genmab AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN22,168 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Genmab AS's current Enterprise Value is MXN350,409 Mil.
Genmab AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN23,700 Mil.
Genmab AS's current Enterprise Value is MXN350,409 Mil.
Genmab AS's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN71,372 Mil.
Genmab AS's current Enterprise Value is MXN350,409 Mil.
Genmab AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN16,474 Mil.
Genmab AS's current Enterprise Value is MXN350,409 Mil.
Genmab AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN15,924 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS Enterprise Value Related Terms
Genmab AS Enterprise Value Historical Data
* Premium members only.
The historical data trend for Genmab AS's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GMABN vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Genmab AS's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Genmab AS's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Genmab AS's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of MXN350,409 Mil mean?
Genmab AS (MEX:GMABN) has a Enterprise Value of MXN350,409 Mil as of Jun. 26, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Genmab AS and its competitors.
Is Genmab AS's Enterprise Value too high?
Genmab AS's current Enterprise Value is MXN350,409 Mil. Overall, Genmab AS has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Enterprise Value compare to VRTX and REGN?
Genmab AS's Enterprise Value of MXN350,409 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Genmab AS and its competitors. Genmab AS's current Enterprise Value is MXN350,409 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (MEX:GMABN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN5,328.99, compared to a current price of MXN4,027.79 — trading 24.4% below its estimated fair value. The current Enterprise Value is MXN350,409 Mil. Genmab AS's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Genmab AS (MEX:GMABN), the current Enterprise Value is MXN350,409 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (MEX:GMABN) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of MXN4,027.79 is trading 24.4% below its estimated GF Value™ of MXN5,328.99.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for MEX:GMABN:
Enterprise Value: MXN350,409 Mil
GF Value™: MXN5,328.99 vs. price of MXN4,027.79 (24.4% below fair value)
No single metric tells the full story. See the MEX:GMABN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
92GF Score
Get the complete analysis for MEX:GMABN
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GMABN has been successfully added to your 
